Northland raised the firm’s price target on Brainsway (BWAY) to $30 from $23 and keeps an Outperform rating on the shares. The firm believes that its FDA-approved SWIFT accelerated protocol and its strategic partnerships will boost both near and long-term prospects, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- BrainsWay Wins Draft Highmark Coverage for Accelerated Deep TMS Depression Protocol
- Brainsway announces draft coverage policy from Highmark for Deep TMS
- BrainsWay Highlights FDA Approval of Neurolief’s At-Home Proliv Rx Device for Treatment-Resistant Depression
- Brainsway announces U.S. FDA granted PMA for Neurolief’s ProlivRx system
- BrainsWay Wins First Insurer Coverage for Accelerated Deep TMS Depression Protocol